CCXI ChemoCentryx Inc

Price (delayed)

$45.53

Market cap

$3.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.84

Enterprise value

$3.2B

Sector: Healthcare
Industry: Biotechnology

Highlights

The quick ratio has surged by 189% year-on-year but it has declined by 16% since the previous quarter
ChemoCentryx's gross profit has soared by 80% YoY but it has decreased by 8% from the previous quarter
ChemoCentryx's net income has decreased by 35% from the previous quarter
The debt is up by 7% QoQ

Key stats

What are the main financial stats of CCXI
Market
Shares outstanding
69.61M
Market cap
$3.17B
Enterprise value
$3.2B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.17
Price to sales (P/S)
46.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.32
Earnings
Revenue
$64.89M
EBIT
-$52.71M
EBITDA
-$49.95M
Free cash flow
-$96.55M
Per share
EPS
-$0.84
Free cash flow per share
-$1.47
Book value per share
$5.57
Revenue per share
$0.99
TBVPS
$7.9
Balance sheet
Total assets
$518.9M
Total liabilities
$133.29M
Debt
$63.07M
Equity
$385.61M
Working capital
$390.01M
Liquidity
Debt to equity
0.16
Current ratio
8.56
Quick ratio
8.47
Net debt/EBITDA
-0.62
Margins
EBITDA margin
-77%
Gross margin
100%
Net margin
-85.3%
Operating margin
-85%
Efficiency
Return on assets
-12.4%
Return on equity
-17.4%
Return on invested capital
-16.3%
Return on capital employed
-11.3%
Return on sales
-81.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CCXI stock price

How has the ChemoCentryx stock price performed over time
Intraday
-2.17%
1 week
-1.68%
1 month
-21.66%
1 year
-7.82%
YTD
-26.47%
QTD
-11.14%

Financial performance

How have ChemoCentryx's revenue and profit performed over time
Revenue
$64.89M
Gross profit
$64.89M
Operating income
-$55.18M
Net income
-$55.36M
Gross margin
100%
Net margin
-85.3%
ChemoCentryx's gross profit has soared by 80% YoY but it has decreased by 8% from the previous quarter
The revenue has soared by 80% YoY but it fell by 8% QoQ
The company's operating margin rose by 47% YoY but it fell by 44% QoQ
The net margin is down by 47% QoQ but it is up by 44% YoY

Growth

What is ChemoCentryx's growth rate over time

Valuation

What is ChemoCentryx stock price valuation
P/E
N/A
P/B
8.17
P/S
46.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.32
The EPS has contracted by 29% from the previous quarter but it has grown by 14% YoY
CCXI's P/B is 52% below its last 4 quarters average of 17.5 and 45% below its 5-year quarterly average of 15.3
The company's equity fell by 4.7% QoQ
The revenue has soared by 80% YoY but it fell by 8% QoQ
The price to sales (P/S) is 57% higher than the 5-year quarterly average of 30.1 but 20% lower than the last 4 quarters average of 59.2

Efficiency

How efficient is ChemoCentryx business performance
The company's return on equity has surged by 78% YoY
The return on invested capital has surged by 59% year-on-year
The ROA has soared by 50% YoY but it has contracted by 12% from the previous quarter
The ROS has contracted by 49% from the previous quarter but it has grown by 45% YoY

Dividends

What is CCXI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CCXI.

Financial health

How did ChemoCentryx financials performed over time
The current ratio has soared by 190% YoY but it has contracted by 15% from the previous quarter
The quick ratio has surged by 189% year-on-year but it has declined by 16% since the previous quarter
The debt is 84% lower than the equity
The debt to equity has decreased by 48% YoY but it has increased by 7% from the previous quarter
The debt is up by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.